Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply available. The reason for the disappointing sales, according to the ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at ...

The latest installment of the “Stop Weight Bias” campaign has brought aboard Eli Lilly ... As sales of Lilly’s GLP-1 medications have continued to skyrocket, the company has made a point ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other momentum stocks. After the Fed's rate cut and a positive inflation report ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

Paulo Nunes dos Santos / Bloomberg via Getty Images Eli Lilly ... while the company launched lower-cost single-use vials of Zepbound. As pharmaceutical giant Eli Lilly (LLY) plans to report ...